Ali Moiin is a Dermatology physician affiliated with Wayne State University. OpenAlex indexes 42 publications with 333 citations (h-index 10); ClinicalTrials.gov lists 2 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
1575 W Big Beaver Rd
Suite C12
Troy, MI 480843525
Telephone
248-643-7677Registry record last updated 6 Oct 2014.
Clinical trials
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/ Refractory Small Cell Lung Cancer
Sponsor: SciTech Development, Inc.
- Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
Sponsor: SciTech Development, Inc.
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
24 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- GENZYME CORPORATIONProgram year202512 payments
- Cipher Pharmaceuticals US LLCProgram year20251 payment
- Galderma Laboratories, L.P.Program year202512 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
26.9%Azole Antifungal11.4%Ketoconazole96%Fluconazole4%Part D≥184 patientsLincosamide Antibacterial5.1%Clindamycin Phosphate100%Part D≥80 patients+ 9 more classes in this area
Dermatology
25.6%Corticosteroid13.9%Triamcinolone Acetonide58%Halobetasol Propionate31%Triamcinolone acetonide10%Fluocinolone Acetonide2%Part D + Part B<11 patientsInterleukin-4 Receptor alpha Antagonist3.9%Dupixent Pen100%Part D≥36 patients+ 6 more classes in this area
Sensory organs
24.9%Corticosteroid24.3%Clobetasol Propionate57%Hydrocortisone20%Betamethasone Dipropionate10%Betamethasone Diprop Augmented8%Betamethasone Valerate3%Desonide2%Part D<11 patientsAminoglycoside Antibacterial0.6%Gentamicin Sulfate100%Part D≥22 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Safety and efficacy of barzolvolimab, an anti–KIT monoclonal antibody, in adults with moderate-to-severe prurigo nodularis: A randomized phase 1b intravenous single dose study
Journal of the American Academy of Dermatology
2025 - Lebrikizumab Improves Atopic Dermatitis in Adult and Adolescent Patients With Skin of Color: 16-Week Results From the ADmirable Study
SKIN The Journal of Cutaneous Medicine
2025
Similar KOLs
Other experts from the same institution or the same specialty.
Sonia Hassan, MD
Wayne State University
Tinnakorn Chaiworapongsa, MD
Wayne State University
Robert Sokol, MD
Wayne State University
Robert Lisak, MD
Wayne State University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”